SITC 2021 | Tumor markers associated with increased survival in Phase II trial of AV-GBM-1

Name: Tumor markers associated with increased survival in Phase II trial of AV-GBM-1
Uploaded: 2021-11-12T00:00:00Z
Duration: 48 s
Description: Daniela Bota, MD, PhD, The University of California, Irvine, Irvine, CA, discusses the tumor markers that were associated with increased survival in the Phase II trial of AV-GBM-1, a dendritic cell vaccine. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.

Daniela Bota • 12 Nov 2021

SITC 2021

Glioblastoma AV-GBM-1

Daniela Bota, MD, PhD, The University of California, Irvine, Irvine, CA, discusses the tumor markers that were associated with increased survival in the Phase II trial of AV-GBM-1, a dendritic cell vaccine. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.